51
|
Abstract
PURPOSE OF REVIEW Epidemiological and clinical studies link low levels of HDL cholesterol (HDL-C) with increased risk of atherosclerotic cardiovascular disease (CVD). However, genetic polymorphisms linked to HDL-C do not associate consistently with CVD risk, and randomized clinical studies of drugs that elevate HDL-C via different mechanisms failed to reduce CVD risk in statin-treated patients with established CVD. New metrics that capture HDL's proposed cardioprotective effects are therefore urgently needed. RECENT FINDINGS Recent studies demonstrate cholesterol efflux capacity (CEC) of serum HDL (serum depleted of cholesterol-rich atherogenic lipoproteins) is an independent and better predictor of incident and prevalent CVD risk than HDL-C. However, it remains unclear whether therapies that increase CEC are cardioprotective. Other key issues are the impact of HDL-targeted therapies on HDL particle size and concentration and the relationship of those changes to CEC and cardioprotection. SUMMARY It is time to end the clinical focus on HDL-C and to understand how HDL's function, protein composition and size contribute to CVD risk. It will also be important to link variations in function and size to HDL-targeted therapies. Developing new metrics for quantifying HDL function, based on better understanding HDL metabolism and macrophage CEC, is critical for achieving these goals.
Collapse
Affiliation(s)
- Graziella E. Ronsein
- Departamento de Bioquímica, Instituto de Química,
Universidade de São Paulo, Brazil
| | - Jay W. Heinecke
- Department of Medicine, University of Washington, Seattle, WA
98109
| |
Collapse
|
52
|
Clouet-Foraison N, Gaie-Levrel F, Gillery P, Delatour V. Advanced lipoprotein testing for cardiovascular diseases risk assessment: a review of the novel approaches in lipoprotein profiling. Clin Chem Lab Med 2017; 55:1453-1464. [PMID: 28593877 DOI: 10.1515/cclm-2017-0091] [Citation(s) in RCA: 14] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/31/2017] [Accepted: 03/27/2017] [Indexed: 02/07/2023]
Abstract
With the increasing prevalence of cardiovascular diseases (CVD) worldwide, finding reliable and clinically relevant biomarkers to predict acute cardiovascular events has been a major aim of the scientific and medical community. Improvements of the understanding of the pathophysiological pathways of the disease highlighted the major role of lipoprotein particles, and these past decades have seen the emergence of a number of new methodologies to separate, measure and quantitate lipoproteins. Those methods, also known as advanced lipoprotein testing methods (ALT), have gained acceptance in the field of CVD risk assessment and have proven their clinical relevance. In the context of worldwide standardization and harmonization of biological assays, efforts have been initiated toward standardization of ALT methods. However, the complexity of lipoprotein particles and the multiple approaches and methodologies reported to quantify them have rendered these initiatives a critical issue. In this context and to better understand these challenges, this review presents a summary of the major methods available for ALT with the aim to point out the major differences in terms of procedures and quantities actually measured and to discuss the resulting comparability issues.
Collapse
|
53
|
Pamir N, Hutchins PM, Ronsein GE, Wei H, Tang C, Das R, Vaisar T, Plow E, Schuster V, Koschinsky ML, Reardon CA, Weinberg R, Dichek DA, Marcovina S, Getz GS, Heinecke JW. Plasminogen promotes cholesterol efflux by the ABCA1 pathway. JCI Insight 2017; 2:92176. [PMID: 28768900 DOI: 10.1172/jci.insight.92176] [Citation(s) in RCA: 35] [Impact Index Per Article: 5.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/09/2016] [Accepted: 06/20/2017] [Indexed: 12/20/2022] Open
Abstract
Using genetic and biochemical approaches, we investigated proteins that regulate macrophage cholesterol efflux capacity (CEC) and ABCA1-specific CEC (ABCA1 CEC), 2 functional assays that predict cardiovascular disease (CVD). Macrophage CEC and the concentration of HDL particles were markedly reduced in mice deficient in apolipoprotein A-I (APOA1) or apolipoprotein E (APOE) but not apolipoprotein A-IV (APOA4). ABCA1 CEC was markedly reduced in APOA1-deficient mice but was barely affected in mice deficient in APOE or APOA4. High-resolution size-exclusion chromatography of plasma produced 2 major peaks of ABCA1 CEC activity. The early-eluting peak, which coeluted with HDL, was markedly reduced in APOA1- or APOE-deficient mice. The late-eluting peak was modestly reduced in APOA1-deficient mice but little affected in APOE- or APOA4-deficient mice. Ion-exchange chromatography and shotgun proteomics suggested that plasminogen (PLG) accounted for a substantial fraction of the ABCA1 CEC activity in the peak not associated with HDL. Human PLG promoted cholesterol efflux by the ABCA1 pathway, and PLG-dependent efflux was inhibited by lipoprotein(a) [Lp(a)]. Our observations identify APOA1, APOE, and PLG as key determinants of CEC. Because PLG and Lp(a) associate with human CVD risk, interplay among the proteins might affect atherosclerosis by regulating cholesterol efflux from macrophages.
Collapse
Affiliation(s)
- Nathalie Pamir
- Department of Medicine, University of Washington, Seattle, Washington, USA
| | - Patrick M Hutchins
- Department of Medicine, University of Washington, Seattle, Washington, USA
| | | | - Hao Wei
- Department of Medicine, University of Washington, Seattle, Washington, USA
| | - Chongren Tang
- Department of Medicine, University of Washington, Seattle, Washington, USA
| | - Riku Das
- Department of Molecular Cardiology, Cleveland Clinic, Cleveland, Ohio, USA
| | - Tomas Vaisar
- Department of Medicine, University of Washington, Seattle, Washington, USA
| | - Edward Plow
- Department of Molecular Cardiology, Cleveland Clinic, Cleveland, Ohio, USA
| | - Volker Schuster
- Hospital for Children and Adolescents, Medical Faculty of Leipzig University, Leipzig, Germany
| | - Marlys L Koschinsky
- Robarts Research Institute, Schulich School of Medicine and Dentistry, The University of Western Ontario, London, Ontario, Canada
| | | | - Richard Weinberg
- Department of Internal Medicine, Wake Forest School of Medicine, Winston-Salem, North Carolina, USA
| | - David A Dichek
- Department of Medicine, University of Washington, Seattle, Washington, USA
| | - Santica Marcovina
- Department of Medicine, University of Washington, Seattle, Washington, USA
| | - Godfrey S Getz
- Department of Pathology, University of Chicago, Chicago, Illinois, USA
| | - Jay W Heinecke
- Department of Medicine, University of Washington, Seattle, Washington, USA
| |
Collapse
|
54
|
Abstract
PURPOSE OF REVIEW To summarize recent provocative findings on conventional and novel metrics of HDL including HDL-C, HDL subclasses and HDL cholesterol efflux capacity as related to menopause. RECENT FINDINGS Pattern of menopause-related changes in HDL-C are not consistent, suggesting a complex relationship between HDL and menopause. Growing body of literature indicates that higher levels of HDL-C may not be consistently cardio-protective in midlife women, suggesting a potential change in other metrics of HDL that could not be captured by the static metric HDL-C. It is also possible that higher HDL-C at certain conditions could be a marker of HDL metabolism dysfunctionality. Significant alterations in other metrics of HDL have been reported after menopause and found to be related to estradiol. SUMMARY The impact of changes in novel metrics of HDL over the menopausal transition on cardiovascular disease (CVD) risk later in life is not clear in women. Much of our understanding of how the menopausal transition may impact HDL metrics comes from cross-sectional studies. Future longitudinal studies are needed to evaluate other metrics of HDL shown to better reflect the cardio-protective capacities of HDL, so that the complex association of menopause, HDL and CVD risk could be characterized.
Collapse
Affiliation(s)
- Samar R El Khoudary
- Department of Epidemiology, University of Pittsburgh Graduate School of Public Health, Pittsburgh, Pennsylvania, USA
| |
Collapse
|
55
|
Clouet-Foraison N, Gaie-Levrel F, Coquelin L, Ebrard G, Gillery P, Delatour V. Absolute Quantification of Bionanoparticles by Electrospray Differential Mobility Analysis: An Application to Lipoprotein Particle Concentration Measurements. Anal Chem 2017; 89:2242-2249. [DOI: 10.1021/acs.analchem.6b02909] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/08/2023]
Affiliation(s)
- Noémie Clouet-Foraison
- Laboratoire National de Métrologie et d’Essais, LNE, Chemistry and Biology Division, 1 rue Gaston Boissier, 75724 Paris Cedex 15, France
| | - Francois Gaie-Levrel
- Laboratoire National de Métrologie et d’Essais, LNE, Chemistry and Biology Division, 1 rue Gaston Boissier, 75724 Paris Cedex 15, France
| | - Loic Coquelin
- Laboratoire National de Métrologie et d’Essais, LNE, Chemistry and Biology Division, 1 rue Gaston Boissier, 75724 Paris Cedex 15, France
| | - Géraldine Ebrard
- Laboratoire National de Métrologie et d’Essais, LNE, Chemistry and Biology Division, 1 rue Gaston Boissier, 75724 Paris Cedex 15, France
| | - Philippe Gillery
- University
of
Reims Champagne-Ardenne, Faculty of Medicine, UMR CNRS/URCA n°7369
and University Hospital of Reims, Laboratory of Pediatric Biology
and Research, 45 rue Cognacq-Jay, 51092 Reims Cedex, France
| | - Vincent Delatour
- Laboratoire National de Métrologie et d’Essais, LNE, Chemistry and Biology Division, 1 rue Gaston Boissier, 75724 Paris Cedex 15, France
| |
Collapse
|
56
|
Karathanasis SK, Freeman LA, Gordon SM, Remaley AT. The Changing Face of HDL and the Best Way to Measure It. Clin Chem 2016; 63:196-210. [PMID: 27879324 DOI: 10.1373/clinchem.2016.257725] [Citation(s) in RCA: 82] [Impact Index Per Article: 10.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/08/2016] [Accepted: 10/26/2016] [Indexed: 01/08/2023]
Abstract
BACKGROUND HDL cholesterol (HDL-C) is a commonly used lipid biomarker for assessing cardiovascular health. While a central focus has been placed on the role of HDL in the reverse cholesterol transport (RCT) process, our appreciation for the other cardioprotective properties of HDL continues to expand with further investigation into the structure and function of HDL and its specific subfractions. The development of novel assays is empowering the research community to assess different aspects of HDL function, which at some point may evolve into new diagnostic tests. CONTENT This review discusses our current understanding of the formation and maturation of HDL particles via RCT, as well as the newly recognized roles of HDL outside RCT. The antioxidative, antiinflammatory, antiapoptotic, antithrombotic, antiinfective, and vasoprotective effects of HDL are all discussed, as are the related methodologies for assessing these different aspects of HDL function. We elaborate on the importance of protein and lipid composition of HDL in health and disease and highlight potential new diagnostic assays based on these parameters. SUMMARY Although multiple epidemiologic studies have confirmed that HDL-C is a strong negative risk marker for cardiovascular disease, several clinical and experimental studies have yielded inconsistent results on the direct role of HDL-C as an antiatherogenic factor. As of yet, our increased understanding of HDL biology has not been translated into successful new therapies, but will undoubtedly depend on the development of alternative ways for measuring HDL besides its cholesterol content.
Collapse
Affiliation(s)
| | - Lita A Freeman
- Lipoprotein Metabolism Section, Cardiovascular-Pulmonary Branch, National Heart, Lung, and Blood Institute, NIH, Bethesda, MD
| | - Scott M Gordon
- Lipoprotein Metabolism Section, Cardiovascular-Pulmonary Branch, National Heart, Lung, and Blood Institute, NIH, Bethesda, MD
| | - Alan T Remaley
- Lipoprotein Metabolism Section, Cardiovascular-Pulmonary Branch, National Heart, Lung, and Blood Institute, NIH, Bethesda, MD.
| |
Collapse
|
57
|
El Khoudary SR, Hutchins PM, Matthews KA, Brooks MM, Orchard TJ, Ronsein GE, Heinecke JW. Cholesterol Efflux Capacity and Subclasses of HDL Particles in Healthy Women Transitioning Through Menopause. J Clin Endocrinol Metab 2016; 101:3419-28. [PMID: 27399353 PMCID: PMC5010578 DOI: 10.1210/jc.2016-2144] [Citation(s) in RCA: 42] [Impact Index Per Article: 5.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/19/2022]
Abstract
CONTEXT Growing evidence challenges the concept that high-density lipoprotein-cholesterol (HDL-C) is cardioprotective after menopause. HDL particle concentration (HDL-P) and cholesterol efflux capacity (CEC) might be better predictors of cardiovascular risk. OBJECTIVE Quantify alterations in HDL-P and CEC during menopause, correlating those changes with alterations in estradiol (E2) and FSH. DESIGN Longitudinal study of HDL metrics before and after menopause as indexed by the final menstrual period (FMP). PARTICIPANTS Forty-six women, mean baseline age 47.1 years, 33% black, 67% white. MAIN OUTCOMES AND MEASURES HDL-P concentration (HDL-PIMA) by calibrated ion mobility analysis (IMA); macrophage CEC with cAMP-stimulated macrophages; ATP-binding cassette transporter A1 (ABCA1)-specific CEC with BHK cells expressing human ABCA1. RESULTS After a median of 2.1 years since FMP, both HDL-C (P = .03) and HDL-PIMA (P = .01) increased, with a selective increase in large HDL-PIMA (P = .01), whereas sizes of medium and small HDL-PIMA were decreased (P < .05). These changes were independent of race, body mass index, and time difference. Macrophage CEC and ABCA1-specific CEC increased after FMP (both P < .001). Greater declines in E2 correlated with larger increases in small HDL-PIMA (P = .01), whereas greater increases in FSH associated with greater reductions in the size of medium HDL-PIMA (P = .04). Macrophage CEC and ABCA1-specific CEC correlated positively with E2 levels only before menopause (P = .04 and .009, respectively). CONCLUSIONS Large HDL-PIMA and CEC increased significantly in the early phase of the menopausal transition. Whether patterns of these alterations differ in late postmenopause is unknown. Further exploration is needed to assess that and to determine whether the reported changes in HDL metrics associate with increased cardiovascular risk after menopause.
Collapse
Affiliation(s)
- Samar R El Khoudary
- Department of Epidemiology (S.R.E.K., K.A.M., M.M.B., T.J.O.), University of Pittsburgh, Pittsburgh, Pennsylvania; Department of Medicine (P.M.H., G.E.R., J.W.H.), University of Washington, Seattle, Washington; Department of Psychiatry (K.A.M.), University of Pittsburgh, Pittsburgh, Pennsylvania
| | - Patrick M Hutchins
- Department of Epidemiology (S.R.E.K., K.A.M., M.M.B., T.J.O.), University of Pittsburgh, Pittsburgh, Pennsylvania; Department of Medicine (P.M.H., G.E.R., J.W.H.), University of Washington, Seattle, Washington; Department of Psychiatry (K.A.M.), University of Pittsburgh, Pittsburgh, Pennsylvania
| | - Karen A Matthews
- Department of Epidemiology (S.R.E.K., K.A.M., M.M.B., T.J.O.), University of Pittsburgh, Pittsburgh, Pennsylvania; Department of Medicine (P.M.H., G.E.R., J.W.H.), University of Washington, Seattle, Washington; Department of Psychiatry (K.A.M.), University of Pittsburgh, Pittsburgh, Pennsylvania
| | - Maria M Brooks
- Department of Epidemiology (S.R.E.K., K.A.M., M.M.B., T.J.O.), University of Pittsburgh, Pittsburgh, Pennsylvania; Department of Medicine (P.M.H., G.E.R., J.W.H.), University of Washington, Seattle, Washington; Department of Psychiatry (K.A.M.), University of Pittsburgh, Pittsburgh, Pennsylvania
| | - Trevor J Orchard
- Department of Epidemiology (S.R.E.K., K.A.M., M.M.B., T.J.O.), University of Pittsburgh, Pittsburgh, Pennsylvania; Department of Medicine (P.M.H., G.E.R., J.W.H.), University of Washington, Seattle, Washington; Department of Psychiatry (K.A.M.), University of Pittsburgh, Pittsburgh, Pennsylvania
| | - Graziella E Ronsein
- Department of Epidemiology (S.R.E.K., K.A.M., M.M.B., T.J.O.), University of Pittsburgh, Pittsburgh, Pennsylvania; Department of Medicine (P.M.H., G.E.R., J.W.H.), University of Washington, Seattle, Washington; Department of Psychiatry (K.A.M.), University of Pittsburgh, Pittsburgh, Pennsylvania
| | - Jay W Heinecke
- Department of Epidemiology (S.R.E.K., K.A.M., M.M.B., T.J.O.), University of Pittsburgh, Pittsburgh, Pennsylvania; Department of Medicine (P.M.H., G.E.R., J.W.H.), University of Washington, Seattle, Washington; Department of Psychiatry (K.A.M.), University of Pittsburgh, Pittsburgh, Pennsylvania
| |
Collapse
|
58
|
Kim DS, Li YK, Bell GA, Burt AA, Vaisar T, Hutchins PM, Furlong CE, Otvos JD, Polak JF, Arnan MK, Kaufman JD, McClelland RL, Longstreth WT, Jarvik GP. Concentration of Smaller High-Density Lipoprotein Particle (HDL-P) Is Inversely Correlated With Carotid Intima Media Thickening After Confounder Adjustment: The Multi Ethnic Study of Atherosclerosis (MESA). J Am Heart Assoc 2016; 5:e002977. [PMID: 27207961 PMCID: PMC4889175 DOI: 10.1161/jaha.115.002977] [Citation(s) in RCA: 30] [Impact Index Per Article: 3.8] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 11/25/2015] [Accepted: 04/12/2016] [Indexed: 12/17/2022]
Abstract
BACKGROUND Recent studies have failed to establish a causal relationship between high-density lipoprotein cholesterol levels (HDL-C) and cardiovascular disease (CVD), shifting focus to other HDL measures. We previously reported that smaller/denser HDL levels are protective against cerebrovascular disease. This study sought to determine which of small+medium HDL particle concentration (HDL-P) or large HDL-P was more strongly associated with carotid intima-media thickening (cIMT) in an ethnically diverse cohort. METHODS AND RESULTS In cross-sectional analyses of participants from the Multi Ethnic Study of Atherosclerosis (MESA), we evaluated the associations of nuclear magnetic resonance spectroscopy-measured small+medium versus large HDL-P with cIMT measured in the common and internal carotid arteries, through linear regression. After adjustment for CVD confounders, low-density lipoprotein cholesterol (LDL-C), HDL-C, and small+medium HDL-P remained significantly and inversely associated with common (coefficient=-1.46 μm; P=0.00037; n=6512) and internal cIMT (coefficient=-3.82 μm; P=0.0051; n=6418) after Bonferroni correction for 4 independent tests (threshold for significance=0.0125; α=0.05/4). Large HDL-P was significantly and inversely associated with both cIMT outcomes before HDL-C adjustment; however, after adjustment for HDL-C, the association of large HDL-P with both common (coefficient=1.55 μm; P=0.30; n=6512) and internal cIMT (coefficient=4.84 μm; P=0.33; n=6418) was attenuated. In a separate sample of 126 men, small/medium HDL-P was more strongly correlated with paraoxonase 1 activity (rp=0.32; P=0.00023) as compared to both total HDL-P (rp=0.27; P=0.0024) and large HDL-P (rp=0.02; P=0.41) measures. CONCLUSIONS Small+medium HDL-P is significantly and inversely correlated with cIMT measurements. Correlation of small+medium HDL-P with cardioprotective paraoxonase 1 activity may reflect a functional aspect of HDL responsible for this finding.
Collapse
Affiliation(s)
- Daniel Seung Kim
- Division of Medical Genetics, Department of Medicine, University of Washington School of Medicine, Seattle, WA Department of Genome Sciences, University of Washington School of Medicine, Seattle, WA Department of Biostatistics, University of Washington School of Public Health, Seattle, WA
| | - Yatong K Li
- Department of Biostatistics, University of Washington School of Public Health, Seattle, WA
| | - Griffith A Bell
- Department of Epidemiology, University of Washington School of Public Health, Seattle, WA
| | - Amber A Burt
- Division of Medical Genetics, Department of Medicine, University of Washington School of Medicine, Seattle, WA
| | - Tomas Vaisar
- Division of Metabolism, Endocrinology, and Nutrition, Department of Medicine, University of Washington School of Medicine, Seattle, WA
| | - Patrick M Hutchins
- Division of Metabolism, Endocrinology, and Nutrition, Department of Medicine, University of Washington School of Medicine, Seattle, WA TSI Incorporated, Shoreview, MN
| | - Clement E Furlong
- Division of Medical Genetics, Department of Medicine, University of Washington School of Medicine, Seattle, WA Department of Genome Sciences, University of Washington School of Medicine, Seattle, WA
| | | | - Joseph F Polak
- Department of Radiology, Tufts University School of Medicine, Boston, MA
| | | | - Joel D Kaufman
- Division of General Medicine, Department of Medicine, University of Washington School of Medicine, Seattle, WA Department of Epidemiology, University of Washington School of Public Health, Seattle, WA Department of Environmental and Occupational Health Sciences, University of Washington School of Public Health, Seattle, WA
| | - Robyn L McClelland
- Department of Biostatistics, University of Washington School of Public Health, Seattle, WA
| | - W T Longstreth
- Department of Neurology, Wake Forest School of Medicine, Winston-Salem, NC Department of Epidemiology, University of Washington School of Public Health, Seattle, WA
| | - Gail P Jarvik
- Division of Medical Genetics, Department of Medicine, University of Washington School of Medicine, Seattle, WA Department of Genome Sciences, University of Washington School of Medicine, Seattle, WA
| |
Collapse
|
59
|
Monette JS, Hutchins PM, Ronsein GE, Wimberger J, Irwin AD, Tang C, Sara JD, Shao B, Vaisar T, Lerman A, Heinecke JW. Patients With Coronary Endothelial Dysfunction Have Impaired Cholesterol Efflux Capacity and Reduced HDL Particle Concentration. Circ Res 2016; 119:83-90. [PMID: 27114438 DOI: 10.1161/circresaha.116.308357] [Citation(s) in RCA: 53] [Impact Index Per Article: 6.6] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 01/20/2016] [Accepted: 04/25/2016] [Indexed: 11/16/2022]
Abstract
RATIONALE Coronary endothelial dysfunction (ED)-an early marker of atherosclerosis-increases the risk of cardiovascular events. OBJECTIVE We tested the hypothesis that cholesterol efflux capacity and high-density lipoprotein (HDL) particle concentration predict coronary ED better than HDL-cholesterol (HDL-C). METHODS AND RESULTS We studied 80 subjects with nonobstructive (<30% stenosis) coronary artery disease. ED was defined as <50% change in coronary blood flow in response to intracoronary infusions of acetylcholine during diagnostic coronary angiography. Cholesterol efflux capacity and HDL particle concentration (HDL-PIMA) were assessed with validated assays. Cholesterol efflux capacity and HDL-PIMA were both strong, inverse predictors of ED (P<0.001 and 0.005, respectively). In contrast, HDL-C and other traditional lipid risk factors did not differ significantly between control and ED subjects. Large HDL particles were markedly decreased in ED subjects (33%; P=0.005). After correction for HDL-C, both efflux capacity and HDL-PIMA remained significant predictors of ED status. HDL-PIMA explained cholesterol efflux capacity more effectively than HDL-C (r=0.54 and 0.36, respectively). The efflux capacities of isolated HDL and serum HDL correlated strongly (r=0.49). CONCLUSIONS Cholesterol efflux capacity and HDL-PIMA are reduced in subjects with coronary ED, independently of HDL-C. Alterations in HDL-PIMA and HDL itself account for a much larger fraction of the variation in cholesterol efflux capacity than does HDL-C. A selective decrease in large HDL particles may contribute to impaired cholesterol efflux capacity in ED subjects. These observations support a role for HDL size, concentration, and function as markers-and perhaps mediators-of coronary atherosclerosis in humans.
Collapse
Affiliation(s)
- Jeffrey S Monette
- From the Division of Metabolism, Endocrinology, and Nutrition, Department of Medicine, University of Washington, Seattle (J.S.M., P.M.H., G.E.R., J.W., A.D.I., C.T., B.S., T.V., J.W.H.); and Division of Cardiovascular Disease, Mayo Clinic, Rochester, MN (J.D.S., A.L.)
| | - Patrick M Hutchins
- From the Division of Metabolism, Endocrinology, and Nutrition, Department of Medicine, University of Washington, Seattle (J.S.M., P.M.H., G.E.R., J.W., A.D.I., C.T., B.S., T.V., J.W.H.); and Division of Cardiovascular Disease, Mayo Clinic, Rochester, MN (J.D.S., A.L.)
| | - Graziella E Ronsein
- From the Division of Metabolism, Endocrinology, and Nutrition, Department of Medicine, University of Washington, Seattle (J.S.M., P.M.H., G.E.R., J.W., A.D.I., C.T., B.S., T.V., J.W.H.); and Division of Cardiovascular Disease, Mayo Clinic, Rochester, MN (J.D.S., A.L.)
| | - Jake Wimberger
- From the Division of Metabolism, Endocrinology, and Nutrition, Department of Medicine, University of Washington, Seattle (J.S.M., P.M.H., G.E.R., J.W., A.D.I., C.T., B.S., T.V., J.W.H.); and Division of Cardiovascular Disease, Mayo Clinic, Rochester, MN (J.D.S., A.L.)
| | - Angela D Irwin
- From the Division of Metabolism, Endocrinology, and Nutrition, Department of Medicine, University of Washington, Seattle (J.S.M., P.M.H., G.E.R., J.W., A.D.I., C.T., B.S., T.V., J.W.H.); and Division of Cardiovascular Disease, Mayo Clinic, Rochester, MN (J.D.S., A.L.)
| | - Chongren Tang
- From the Division of Metabolism, Endocrinology, and Nutrition, Department of Medicine, University of Washington, Seattle (J.S.M., P.M.H., G.E.R., J.W., A.D.I., C.T., B.S., T.V., J.W.H.); and Division of Cardiovascular Disease, Mayo Clinic, Rochester, MN (J.D.S., A.L.)
| | - Jaskanwal D Sara
- From the Division of Metabolism, Endocrinology, and Nutrition, Department of Medicine, University of Washington, Seattle (J.S.M., P.M.H., G.E.R., J.W., A.D.I., C.T., B.S., T.V., J.W.H.); and Division of Cardiovascular Disease, Mayo Clinic, Rochester, MN (J.D.S., A.L.)
| | - Baohai Shao
- From the Division of Metabolism, Endocrinology, and Nutrition, Department of Medicine, University of Washington, Seattle (J.S.M., P.M.H., G.E.R., J.W., A.D.I., C.T., B.S., T.V., J.W.H.); and Division of Cardiovascular Disease, Mayo Clinic, Rochester, MN (J.D.S., A.L.)
| | - Tomas Vaisar
- From the Division of Metabolism, Endocrinology, and Nutrition, Department of Medicine, University of Washington, Seattle (J.S.M., P.M.H., G.E.R., J.W., A.D.I., C.T., B.S., T.V., J.W.H.); and Division of Cardiovascular Disease, Mayo Clinic, Rochester, MN (J.D.S., A.L.)
| | - Amir Lerman
- From the Division of Metabolism, Endocrinology, and Nutrition, Department of Medicine, University of Washington, Seattle (J.S.M., P.M.H., G.E.R., J.W., A.D.I., C.T., B.S., T.V., J.W.H.); and Division of Cardiovascular Disease, Mayo Clinic, Rochester, MN (J.D.S., A.L.)
| | - Jay W Heinecke
- From the Division of Metabolism, Endocrinology, and Nutrition, Department of Medicine, University of Washington, Seattle (J.S.M., P.M.H., G.E.R., J.W., A.D.I., C.T., B.S., T.V., J.W.H.); and Division of Cardiovascular Disease, Mayo Clinic, Rochester, MN (J.D.S., A.L.).
| |
Collapse
|
60
|
Amigó N, Mallol R, Heras M, Martínez-Hervás S, Blanco Vaca F, Escolà-Gil JC, Plana N, Yanes Ó, Masana L, Correig X. Lipoprotein hydrophobic core lipids are partially extruded to surface in smaller HDL: "Herniated" HDL, a common feature in diabetes. Sci Rep 2016; 6:19249. [PMID: 26778677 PMCID: PMC4726105 DOI: 10.1038/srep19249] [Citation(s) in RCA: 22] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [Abstract] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/03/2015] [Accepted: 11/30/2015] [Indexed: 11/09/2022] Open
Abstract
Recent studies have shown that pharmacological increases in HDL cholesterol concentrations do not necessarily translate into clinical benefits for patients, raising concerns about its predictive value for cardiovascular events. Here we hypothesize that the size-modulated lipid distribution within HDL particles is compromised in metabolic disorders that have abnormal HDL particle sizes, such as type 2 diabetes mellitus (DM2). By using NMR spectroscopy combined with a biochemical volumetric model we determined the size and spatial lipid distribution of HDL subclasses in a cohort of 26 controls and 29 DM2 patients before and after two drug treatments, one with niacin plus laropiprant and another with fenofibrate as an add-on to simvastatin. We further characterized the HDL surface properties using atomic force microscopy and fluorescent probes to show an abnormal lipid distribution within smaller HDL particles, a subclass particularly enriched in the DM2 patients. The reduction in the size, force cholesterol esters and triglycerides to emerge from the HDL core to the surface, making the outer surface of HDL more hydrophobic. Interestingly, pharmacological interventions had no effect on this undesired configuration, which may explain the lack of clinical benefits in DM2 subjects.
Collapse
Affiliation(s)
- Núria Amigó
- Metabolomics Platform, Department of Electronic Engineering, Rovira i Virgili University, IISPV, Av. PaÏsos Catalans 26, 43007, Tarragona, Spain.,Spanish Biomedical Research Centre in Diabetes and Associated Metabolic Disorders (CIBERDEM), C. Monforte de Lemos 3-5, 28029, Madrid, Spain
| | - Roger Mallol
- Metabolomics Platform, Department of Electronic Engineering, Rovira i Virgili University, IISPV, Av. PaÏsos Catalans 26, 43007, Tarragona, Spain.,Spanish Biomedical Research Centre in Diabetes and Associated Metabolic Disorders (CIBERDEM), C. Monforte de Lemos 3-5, 28029, Madrid, Spain
| | - Mercedes Heras
- Spanish Biomedical Research Centre in Diabetes and Associated Metabolic Disorders (CIBERDEM), C. Monforte de Lemos 3-5, 28029, Madrid, Spain.,Vascular Medicine and Metabolism Unit, Research Unit on Lipids and Atherosclerosis, Sant Joan University Hospital, Rovira i Virgili University, IISPV, C. Sant Joan s/n, 43201, Reus, Spain
| | - Sergio Martínez-Hervás
- Spanish Biomedical Research Centre in Diabetes and Associated Metabolic Disorders (CIBERDEM), C. Monforte de Lemos 3-5, 28029, Madrid, Spain.,Endocrinology and Nutrition Department, Hospital Clinico Universitario, INCLIVA, Department of Medicine, University of Valencia, Av. Blasco Ibañez 17, 46010, Valencia, Spain
| | - Francisco Blanco Vaca
- Spanish Biomedical Research Centre in Diabetes and Associated Metabolic Disorders (CIBERDEM), C. Monforte de Lemos 3-5, 28029, Madrid, Spain.,Institut d'Investigacions Biomèdiques (IIB) Sant Pau, Antoni M. Claret 167, 08025, Barcelona, spain.,Departament de Bioquímica i Biologia Molecular, Universitat Autònoma de Barcelona (UAB), Edifici M. Campus de la UAB, 08193, Bellaterra, Spain
| | - Joan Carles Escolà-Gil
- Spanish Biomedical Research Centre in Diabetes and Associated Metabolic Disorders (CIBERDEM), C. Monforte de Lemos 3-5, 28029, Madrid, Spain.,Institut d'Investigacions Biomèdiques (IIB) Sant Pau, Antoni M. Claret 167, 08025, Barcelona, spain.,Departament de Bioquímica i Biologia Molecular, Universitat Autònoma de Barcelona (UAB), Edifici M. Campus de la UAB, 08193, Bellaterra, Spain
| | - Núria Plana
- Spanish Biomedical Research Centre in Diabetes and Associated Metabolic Disorders (CIBERDEM), C. Monforte de Lemos 3-5, 28029, Madrid, Spain.,Vascular Medicine and Metabolism Unit, Research Unit on Lipids and Atherosclerosis, Sant Joan University Hospital, Rovira i Virgili University, IISPV, C. Sant Joan s/n, 43201, Reus, Spain
| | - Óscar Yanes
- Metabolomics Platform, Department of Electronic Engineering, Rovira i Virgili University, IISPV, Av. PaÏsos Catalans 26, 43007, Tarragona, Spain.,Spanish Biomedical Research Centre in Diabetes and Associated Metabolic Disorders (CIBERDEM), C. Monforte de Lemos 3-5, 28029, Madrid, Spain
| | - Lluís Masana
- Spanish Biomedical Research Centre in Diabetes and Associated Metabolic Disorders (CIBERDEM), C. Monforte de Lemos 3-5, 28029, Madrid, Spain.,Vascular Medicine and Metabolism Unit, Research Unit on Lipids and Atherosclerosis, Sant Joan University Hospital, Rovira i Virgili University, IISPV, C. Sant Joan s/n, 43201, Reus, Spain
| | - Xavier Correig
- Metabolomics Platform, Department of Electronic Engineering, Rovira i Virgili University, IISPV, Av. PaÏsos Catalans 26, 43007, Tarragona, Spain.,Spanish Biomedical Research Centre in Diabetes and Associated Metabolic Disorders (CIBERDEM), C. Monforte de Lemos 3-5, 28029, Madrid, Spain
| |
Collapse
|
61
|
Chouinard CD, Wei MS, Beekman CR, Kemperman RHJ, Yost RA. Ion Mobility in Clinical Analysis: Current Progress and Future Perspectives. Clin Chem 2016; 62:124-33. [DOI: 10.1373/clinchem.2015.238840] [Citation(s) in RCA: 75] [Impact Index Per Article: 9.4] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/02/2015] [Accepted: 10/29/2015] [Indexed: 11/06/2022]
Abstract
Abstract
BACKGROUND
Ion mobility spectrometry (IMS) is a rapid separation tool that can be coupled with several sampling/ionization methods, other separation techniques (e.g., chromatography), and various detectors (e.g., mass spectrometry). This technique has become increasingly used in the last 2 decades for applications ranging from illicit drug and chemical warfare agent detection to structural characterization of biological macromolecules such as proteins. Because of its rapid speed of analysis, IMS has recently been investigated for its potential use in clinical laboratories.
CONTENT
This review article first provides a brief introduction to ion mobility operating principles and instrumentation. Several current applications will then be detailed, including investigation of rapid ambient sampling from exhaled breath and other volatile compounds and mass spectrometric imaging for localization of target compounds. Additionally, current ion mobility research in relevant fields (i.e., metabolomics) will be discussed as it pertains to potential future application in clinical settings.
SUMMARY
This review article provides the authors' perspective on the future of ion mobility implementation in the clinical setting, with a focus on ambient sampling methods that allow IMS to be used as a “bedside” standalone technique for rapid disease screening and methods for improving the analysis of complex biological samples such as blood plasma and urine.
Collapse
Affiliation(s)
| | - Michael S Wei
- Department of Chemistry, University of Florida, Gainesville, FL
| | | | | | - Richard A Yost
- Department of Chemistry, University of Florida, Gainesville, FL
- Southeast Center for Integrated Metabolomics (SECIM), University of Florida, Gainesville, FL
| |
Collapse
|
62
|
Ronsein GE, Hutchins PM, Isquith D, Vaisar T, Zhao XQ, Heinecke JW. Niacin Therapy Increases High-Density Lipoprotein Particles and Total Cholesterol Efflux Capacity But Not ABCA1-Specific Cholesterol Efflux in Statin-Treated Subjects. Arterioscler Thromb Vasc Biol 2015; 36:404-11. [PMID: 26681752 DOI: 10.1161/atvbaha.115.306268] [Citation(s) in RCA: 49] [Impact Index Per Article: 5.4] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/23/2015] [Accepted: 12/09/2015] [Indexed: 11/16/2022]
Abstract
OBJECTIVE We investigated relationships between statin and niacin/statin combination therapy and the concentration of high-density lipoprotein particles (HDL-P) and cholesterol efflux capacity, 2 HDL metrics that might better assess cardiovascular disease risk than HDL-cholesterol (HDL-C) levels. APPROACH In the Carotid Plaque Composition Study, 126 subjects with a history of cardiovascular disease were randomized to atorvastatin or combination therapy (atorvastatin/niacin). At baseline and after 1 year of treatment, the concentration of HDL and its 3 subclasses (small, medium, and large) were quantified by calibrated ion mobility analysis (HDL-PIMA). We also measured total cholesterol efflux from macrophages and ATP-binding cassette transporter A1 (ABCA1)-specific cholesterol efflux capacity. RESULTS Atorvastatin decreased low-density lipoprotein cholesterol by 39% and raised HDL-C by 11% (P=0.0001) but did not increase HDL-PIMA or macrophage cholesterol efflux. Combination therapy raised HDL-C by 39% (P<0.0001) but increased HDL-PIMA by only 14%. Triglyceride levels did not correlate with HDL-PIMA (P=0.39), in contrast to their strongly negative correlation with HDL-C (P<0.0001). Combination therapy increased macrophage cholesterol efflux capacity (16%, P<0.0001) but not ABCA1-specific efflux. ABCA1-specific cholesterol efflux capacity decreased significantly (P=0.013) in statin-treated subjects, with or without niacin therapy. CONCLUSIONS Statin therapy increased HDL-C levels but failed to increase HDL-PIMA. It also reduced ABCA1-specific cholesterol efflux capacity. Adding niacin to statin therapy increased HDL-C and macrophage efflux, but had much less effect on HDL-PIMA. It also failed to improve ABCA1-specific efflux, a key cholesterol exporter in macrophages. Our observations raise the possibility that niacin might not target the relevant atheroprotective population of HDL.
Collapse
Affiliation(s)
| | | | - Daniel Isquith
- From the Department of Medicine, University of Washington, Seattle
| | - Tomas Vaisar
- From the Department of Medicine, University of Washington, Seattle
| | - Xue-Qiao Zhao
- From the Department of Medicine, University of Washington, Seattle
| | - Jay W Heinecke
- From the Department of Medicine, University of Washington, Seattle.
| |
Collapse
|
63
|
Pamir N, Hutchins P, Ronsein G, Vaisar T, Reardon CA, Getz GS, Lusis AJ, Heinecke JW. Proteomic analysis of HDL from inbred mouse strains implicates APOE associated with HDL in reduced cholesterol efflux capacity via the ABCA1 pathway. J Lipid Res 2015; 57:246-57. [PMID: 26673204 PMCID: PMC4727420 DOI: 10.1194/jlr.m063701] [Citation(s) in RCA: 40] [Impact Index Per Article: 4.4] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/11/2015] [Indexed: 12/15/2022] Open
Abstract
Cholesterol efflux capacity associates strongly and negatively with the incidence and prevalence of human CVD. We investigated the relationships of HDL’s size and protein cargo with its cholesterol efflux capacity using APOB-depleted serum and HDLs isolated from five inbred mouse strains with different susceptibilities to atherosclerosis. Like humans, mouse HDL carried >70 proteins linked to lipid metabolism, the acute-phase response, proteinase inhibition, and the immune system. HDL’s content of specific proteins strongly correlated with its size and cholesterol efflux capacity, suggesting that its protein cargo regulates its function. Cholesterol efflux capacity with macrophages strongly and positively correlated with retinol binding protein 4 (RBP4) and PLTP, but not APOA1. In contrast, ABCA1-specific cholesterol efflux correlated strongly with HDL’s content of APOA1, APOC3, and APOD, but not RBP4 and PLTP. Unexpectedly, APOE had a strong negative correlation with ABCA1-specific cholesterol efflux capacity. Moreover, the ABCA1-specific cholesterol efflux capacity of HDL isolated from APOE-deficient mice was significantly greater than that of HDL from wild-type mice. Our observations demonstrate that the HDL-associated APOE regulates HDL’s ABCA1-specific cholesterol efflux capacity. These findings may be clinically relevant because HDL’s APOE content associates with CVD risk and ABCA1 deficiency promotes unregulated cholesterol accumulation in human macrophages.
Collapse
Affiliation(s)
- Nathalie Pamir
- Department of Medicine, University of Washington, Seattle, WA
| | | | | | - Tomas Vaisar
- Department of Medicine, University of Washington, Seattle, WA
| | | | - Godfrey S Getz
- Department of Pathology, University of Chicago, Chicago, IL
| | - Aldons J Lusis
- Department of Genetics, University of California at Los Angeles, Los Angeles, CA
| | - Jay W Heinecke
- Department of Medicine, University of Washington, Seattle, WA
| |
Collapse
|
64
|
Han CY, Tang C, Guevara ME, Wei H, Wietecha T, Shao B, Subramanian S, Omer M, Wang S, O'Brien KD, Marcovina SM, Wight TN, Vaisar T, de Beer MC, de Beer FC, Osborne WR, Elkon KB, Chait A. Serum amyloid A impairs the antiinflammatory properties of HDL. J Clin Invest 2015; 126:266-81. [PMID: 26642365 DOI: 10.1172/jci83475] [Citation(s) in RCA: 107] [Impact Index Per Article: 11.9] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/01/2015] [Accepted: 10/29/2015] [Indexed: 01/25/2023] Open
Abstract
HDL from healthy humans and lean mice inhibits palmitate-induced adipocyte inflammation; however, the effect of the inflammatory state on the functional properties of HDL on adipocytes is unknown. Here, we found that HDL from mice injected with AgNO3 fails to inhibit palmitate-induced inflammation and reduces cholesterol efflux from 3T3-L1 adipocytes. Moreover, HDL isolated from obese mice with moderate inflammation and humans with systemic lupus erythematosus had similar effects. Since serum amyloid A (SAA) concentrations in HDL increase with inflammation, we investigated whether elevated SAA is a causal factor in HDL dysfunction. HDL from AgNO3-injected mice lacking Saa1.1 and Saa2.1 exhibited a partial restoration of antiinflammatory and cholesterol efflux properties in adipocytes. Conversely, incorporation of SAA into HDL preparations reduced antiinflammatory properties but not to the same extent as HDL from AgNO3-injected mice. SAA-enriched HDL colocalized with cell surface-associated extracellular matrix (ECM) of adipocytes, suggesting impaired access to the plasma membrane. Enzymatic digestion of proteoglycans in the ECM restored the ability of SAA-containing HDL to inhibit palmitate-induced inflammation and cholesterol efflux. Collectively, these findings indicate that inflammation results in a loss of the antiinflammatory properties of HDL on adipocytes, which appears to partially result from the SAA component of HDL binding to cell-surface proteoglycans, thereby preventing access of HDL to the plasma membrane.
Collapse
|
65
|
Abstract
PURPOSE OF REVIEW Randomized clinical trials provide strong evidence that pharmacological elevation of HDL-cholesterol (HDL-C) fails to reduce cardiovascular disease (CVD) risk in statin-treated humans. It is thus critical to identify new metrics that capture HDL's cardioprotective effects. RECENT FINDINGS We review recent evidence that HDL's cholesterol efflux capacity is a strong inverse predictor of incident and prevalent CVD in humans. In light of those findings, we assess the proposal that impaired macrophage cholesterol efflux to HDL contributes to disease risk. We also discuss recent studies implicating small HDL particles in cholesterol efflux from macrophages. SUMMARY These observations lay the foundation for a new approach to understanding mechanistically how HDL's functional properties help reduce CVD risk.
Collapse
Affiliation(s)
- Patrick M Hutchins
- Department of Medicine, University of Washington, Seattle, Washington, USA
| | | |
Collapse
|
66
|
Dinnes DLM, Nicholls SJ, Jessup W, Kritharides L. HDL heterogeneity and serum efflux capacity. Curr Opin Lipidol 2015; 26:350-2. [PMID: 26164729 DOI: 10.1097/bor.0b013e32834b1fb1] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
Affiliation(s)
- Donna Lee M Dinnes
- aAtherosclerosis Laboratory, ANZAC Research Institute, University of Sydney, Sydney, NSW bSouth Australian Health and Medical Research Institute, University of Adelaide, Adelaide, SA cDepartment of Cardiology, Concord Repatriation General Hospital, Sydney, NSW, Australia
| | | | | | | |
Collapse
|
67
|
Cao P, Pan H, Xiao T, Zhou T, Guo J, Su Z. Advances in the Study of the Antiatherogenic Function and Novel Therapies for HDL. Int J Mol Sci 2015. [PMID: 26225968 PMCID: PMC4581191 DOI: 10.3390/ijms160817245] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/12/2022] Open
Abstract
The hypothesis that raising high-density lipoprotein cholesterol (HDL-C) levels could improve the risk for cardiovascular disease (CVD) is facing challenges. There is multitudinous clear clinical evidence that the latest failures of HDL-C-raising drugs show no clear association with risks for CVD. At the genetic level, recent research indicates that steady-state HDL-C concentrations may provide limited information regarding the potential antiatherogenic functions of HDL. It is evident that the newer strategies may replace therapeutic approaches to simply raise plasma HDL-C levels. There is an urgent need to identify an efficient biomarker that accurately predicts the increased risk of atherosclerosis (AS) in patients and that may be used for exploring newer therapeutic targets. Studies from recent decades show that the composition, structure and function of circulating HDL are closely associated with high cardiovascular risk. A vast amount of data demonstrates that the most important mechanism through which HDL antagonizes AS involves the reverse cholesterol transport (RCT) process. Clinical trials of drugs that specifically target HDL have so far proven disappointing, so it is necessary to carry out review on the HDL therapeutics.
Collapse
Affiliation(s)
- Peiqiu Cao
- Key Research Center of Liver Regulation for Hyperlipemia SATCM/Class III, Laboratory of Metabolism SATCM, Guangdong TCM Key Laboratory for Metabolic Diseases, Guangdong Pharmaceutical University, Guangzhou 510006, China.
| | - Haitao Pan
- Key Research Center of Liver Regulation for Hyperlipemia SATCM/Class III, Laboratory of Metabolism SATCM, Guangdong TCM Key Laboratory for Metabolic Diseases, Guangdong Pharmaceutical University, Guangzhou 510006, China.
| | - Tiancun Xiao
- Inorganic Chemistry Laboratory, University of Oxford, South Parks Road, Oxford OX1 3QR, UK.
- Guangzhou Boxabio Ltd., D-106 Guangzhou International Business Incubator, Guangzhou 510530, China.
| | - Ting Zhou
- Guangzhou Boxabio Ltd., D-106 Guangzhou International Business Incubator, Guangzhou 510530, China.
| | - Jiao Guo
- Key Research Center of Liver Regulation for Hyperlipemia SATCM/Class III, Laboratory of Metabolism SATCM, Guangdong TCM Key Laboratory for Metabolic Diseases, Guangdong Pharmaceutical University, Guangzhou 510006, China.
| | - Zhengquan Su
- Key Research Center of Liver Regulation for Hyperlipemia SATCM/Class III, Laboratory of Metabolism SATCM, Guangdong TCM Key Laboratory for Metabolic Diseases, Guangdong Pharmaceutical University, Guangzhou 510006, China.
| |
Collapse
|
68
|
Heinecke JW. Small HDL promotes cholesterol efflux by the ABCA1 pathway in macrophages: implications for therapies targeted to HDL. Circ Res 2015; 116:1101-3. [PMID: 25814677 DOI: 10.1161/circresaha.115.306052] [Citation(s) in RCA: 24] [Impact Index Per Article: 2.7] [Reference Citation Analysis] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Affiliation(s)
- Jay W Heinecke
- From the Department of Medicine, University of Washington, Seattle, WA.
| |
Collapse
|
69
|
Kim DS, Burt AA, Ranchalis JE, Vuletic S, Vaisar T, Li WF, Rosenthal EA, Dong W, Eintracht JF, Motulsky AG, Brunzell JD, Albers JJ, Furlong CE, Jarvik GP. PLTP activity inversely correlates with CAAD: effects of PON1 enzyme activity and genetic variants on PLTP activity. J Lipid Res 2015; 56:1351-62. [PMID: 26009633 DOI: 10.1194/jlr.p058032] [Citation(s) in RCA: 14] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/30/2015] [Indexed: 01/07/2023] Open
Abstract
Recent studies have failed to demonstrate a causal cardioprotective effect of HDL cholesterol levels, shifting focus to the functional aspects of HDL. Phospholipid transfer protein (PLTP) is an HDL-associated protein involved in reverse cholesterol transport. This study sought to determine the genetic and nongenetic predictors of plasma PLTP activity (PLTPa), and separately, to determine whether PLTPa predicted carotid artery disease (CAAD). PLTPa was measured in 1,115 European ancestry participants from a case-control study of CAAD. A multivariate logistic regression model was used to elucidate the relationship between PLTPa and CAAD. Separately, a stepwise linear regression determined the nongenetic clinical and laboratory characteristics that best predicted PLTPa. A final stepwise regression considering both nongenetic and genetic variables identified the combination of covariates that explained maximal PLTPa variance. PLTPa was significantly associated with CAAD (7.90 × 10(-9)), with a 9% decrease in odds of CAAD per 1 unit increase in PLTPa (odds ratio = 0.91). Triglyceride levels (P = 0.0042), diabetes (P = 7.28 × 10(-5)), paraoxonase 1 (PON1) activity (P = 0.019), statin use (P = 0.026), PLTP SNP rs4810479 (P = 6.38 × 10(-7)), and PCIF1 SNP rs181914932 (P = 0.041) were all significantly associated with PLTPa. PLTPa is significantly inversely correlated with CAAD. Furthermore, we report a novel association between PLTPa and PON1 activity, a known predictor of CAAD.
Collapse
Affiliation(s)
- Daniel Seung Kim
- Division of Medical Genetics, Department of Medicine, University of Washington School of Medicine, Seattle, WA Department of Genome Sciences, University of Washington School of Medicine, Seattle, WA Department of Biostatistics, University of Washington School of Public Health, Seattle, WA
| | - Amber A Burt
- Division of Medical Genetics, Department of Medicine, University of Washington School of Medicine, Seattle, WA
| | - Jane E Ranchalis
- Division of Medical Genetics, Department of Medicine, University of Washington School of Medicine, Seattle, WA
| | - Simona Vuletic
- Northwest Lipid Metabolism and Diabetes Research Laboratories, Seattle, WA Division of Metabolism, Endocrinology, and Nutrition, Department of Medicine, University of Washington School of Medicine, Seattle, WA
| | - Tomas Vaisar
- Division of Metabolism, Endocrinology, and Nutrition, Department of Medicine, University of Washington School of Medicine, Seattle, WA
| | - Wan-Fen Li
- Division of Medical Genetics, Department of Medicine, University of Washington School of Medicine, Seattle, WA
| | - Elisabeth A Rosenthal
- Division of Medical Genetics, Department of Medicine, University of Washington School of Medicine, Seattle, WA
| | - Weijiang Dong
- Northwest Lipid Metabolism and Diabetes Research Laboratories, Seattle, WA Division of Metabolism, Endocrinology, and Nutrition, Department of Medicine, University of Washington School of Medicine, Seattle, WA Department of Human Anatomy and Histology and Embryology, Xi'an Jiaotong University School of Medicine, Xi'an 710061, People's Republic of China
| | - Jason F Eintracht
- Department of General Medicine, Virginia Mason Medical Center, Seattle, WA
| | - Arno G Motulsky
- Division of Medical Genetics, Department of Medicine, University of Washington School of Medicine, Seattle, WA Department of Genome Sciences, University of Washington School of Medicine, Seattle, WA
| | - John D Brunzell
- Division of Metabolism, Endocrinology, and Nutrition, Department of Medicine, University of Washington School of Medicine, Seattle, WA
| | - John J Albers
- Northwest Lipid Metabolism and Diabetes Research Laboratories, Seattle, WA Division of Metabolism, Endocrinology, and Nutrition, Department of Medicine, University of Washington School of Medicine, Seattle, WA
| | - Clement E Furlong
- Division of Medical Genetics, Department of Medicine, University of Washington School of Medicine, Seattle, WA Department of Genome Sciences, University of Washington School of Medicine, Seattle, WA
| | - Gail P Jarvik
- Division of Medical Genetics, Department of Medicine, University of Washington School of Medicine, Seattle, WA Department of Genome Sciences, University of Washington School of Medicine, Seattle, WA
| |
Collapse
|
70
|
Vaisar T, Tang C, Babenko I, Hutchins P, Wimberger J, Suffredini AF, Heinecke JW. Inflammatory remodeling of the HDL proteome impairs cholesterol efflux capacity. J Lipid Res 2015; 56:1519-30. [PMID: 25995210 DOI: 10.1194/jlr.m059089] [Citation(s) in RCA: 137] [Impact Index Per Article: 15.2] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/09/2015] [Indexed: 12/17/2022] Open
Abstract
Recent studies demonstrate that HDL's ability to promote cholesterol efflux from macrophages associates strongly with cardioprotection in humans independently of HDL-cholesterol (HDL-C) and apoA-I, HDL's major protein. However, the mechanisms that impair cholesterol efflux capacity during vascular disease are unclear. Inflammation, a well-established risk factor for cardiovascular disease, has been shown to impair HDL's cholesterol efflux capacity. We therefore tested the hypothesis that HDL's impaired efflux capacity is mediated by specific changes of its protein cargo. Humans with acute inflammation induced by low-level endotoxin had unchanged HDL-C levels, but their HDL-C efflux capacity was significantly impaired. Proteomic analyses demonstrated that HDL's cholesterol efflux capacity correlated inversely with HDL content of serum amyloid A (SAA)1 and SAA2. In mice, acute inflammation caused a marked impairment of HDL-C efflux capacity that correlated with a large increase in HDL SAA. In striking contrast, the efflux capacity of mouse inflammatory HDL was preserved with genetic ablation of SAA1 and SAA2. Our observations indicate that the inflammatory impairment of HDL-C efflux capacity is due in part to SAA-mediated remodeling of HDL's protein cargo.
Collapse
Affiliation(s)
- Tomáš Vaisar
- Department of Medicine, University of Washington, Seattle, WA 98105
| | - Chongren Tang
- Department of Medicine, University of Washington, Seattle, WA 98105
| | - Ilona Babenko
- Department of Medicine, University of Washington, Seattle, WA 98105
| | - Patrick Hutchins
- Department of Medicine, University of Washington, Seattle, WA 98105
| | - Jake Wimberger
- Department of Medicine, University of Washington, Seattle, WA 98105
| | - Anthony F Suffredini
- Critical Care Medicine Department, National Institutes of Health, Bethesda, MD 20892
| | - Jay W Heinecke
- Department of Medicine, University of Washington, Seattle, WA 98105
| |
Collapse
|
71
|
Remaley AT. HDL cholesterol/HDL particle ratio: a new measure of HDL function? J Am Coll Cardiol 2015; 65:364-366. [PMID: 25634835 DOI: 10.1016/j.jacc.2014.11.018] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 11/03/2014] [Accepted: 11/05/2014] [Indexed: 01/14/2023]
|
72
|
Abstract
PURPOSE OF REVIEW We provide a historical perspective of how high-density lipoprotein (HDL) cholesterol became a clinical standard, the evidence in favor of HDL function as a more appropriate indication of HDL's antiatherogenic nature, and the options ahead. RECENT FINDINGS Recent studies have demonstrated a strong relationship between the cholesterol efflux capacity of plasma and prevalent cardiovascular disease (CVD) and CVD event risk, indicating the utility of HDL function as a diagnostic/prognostic of CVD. SUMMARY We will present how HDL cholesterol came to be the standard proxy of HDL function, the key observations that drew its clinical relevance into question, and the pros and cons of commercially available approaches to measuring HDL function.
Collapse
Affiliation(s)
- Michael N Oda
- Children's Hospital Oakland Research Institute, Oakland, California, USA
| |
Collapse
|
73
|
Underappreciated Opportunities for High-Density Lipoprotein Particles in Risk Stratification and Potential Targets of Therapy. Cardiovasc Drugs Ther 2015; 29:41-50. [DOI: 10.1007/s10557-014-6567-0] [Citation(s) in RCA: 14] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/20/2022]
|
74
|
Mallol R, Amigó N, Rodríguez MA, Heras M, Vinaixa M, Plana N, Rock E, Ribalta J, Yanes O, Masana L, Correig X. Liposcale: a novel advanced lipoprotein test based on 2D diffusion-ordered 1H NMR spectroscopy. J Lipid Res 2015; 56:737-746. [PMID: 25568061 DOI: 10.1194/jlr.d050120] [Citation(s) in RCA: 125] [Impact Index Per Article: 13.9] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
Determination of lipoprotein particle size and number using advanced lipoprotein tests (ALTs) is of particular importance to improve cardiovascular risk prediction. Here we present the Liposcale test, a novel ALT based on 2D diffusion-ordered (1)H NMR spectroscopy. Our method uses diffusion coefficients to provide a direct measure of the mean particle sizes and numbers. Using 177 plasma samples from healthy individuals and the concentration of ApoB and ApoA from isolated lipoprotein fractions, our test showed a stronger correlation between the NMR-derived lipoprotein particle numbers and apolipoprotein concentrations than the LipoProfile(®) test commercialized by Liposcience. We also converted LDL particle numbers to ApoB equivalents (milligrams per deciliter) and our test yielded similar values of LDL-ApoB to the LipoProfile(®) test (absolute mean bias of 8.5 and 7.4 mg/dl, respectively). In addition, our HDL particle number values were more concordant with the calibrated values determined recently using ion mobility. Finally, principal component analysis distinguished type 2 diabetic patients with and without atherogenic dyslipidemia (AD) on a second cohort of 307 subjects characterized using the Liposcale test (area under the curve = 0.88) and showed concordant relationships between variables explaining AD. Altogether, our method provides reproducible and reliable characterization of lipoprotein particles and it is applicable to pathological states such as AD.
Collapse
Affiliation(s)
- Roger Mallol
- Department of Electronic Engineering, Universitat Rovira i Virgili, IISPV, Tarragona, Spain; Spanish Biomedical Research Centre in Diabetes and Associated Metabolic Disorders (CIBERDEM), Madrid, Spain; Biosfer Teslab, Reus, Spain.
| | - Núria Amigó
- Department of Electronic Engineering, Universitat Rovira i Virgili, IISPV, Tarragona, Spain; Spanish Biomedical Research Centre in Diabetes and Associated Metabolic Disorders (CIBERDEM), Madrid, Spain; Biosfer Teslab, Reus, Spain
| | - Miguel A Rodríguez
- Spanish Biomedical Research Centre in Diabetes and Associated Metabolic Disorders (CIBERDEM), Madrid, Spain; Centre for Omic Sciences (COS) Universitat Rovira i Virgili, IISPV, Reus, Spain
| | - Mercedes Heras
- Spanish Biomedical Research Centre in Diabetes and Associated Metabolic Disorders (CIBERDEM), Madrid, Spain; Research Unit on Lipids and Atherosclerosis, Sant Joan University Hospital, Universitat Rovira i Virgili, IISPV, Reus, Spain
| | - Maria Vinaixa
- Department of Electronic Engineering, Universitat Rovira i Virgili, IISPV, Tarragona, Spain; Spanish Biomedical Research Centre in Diabetes and Associated Metabolic Disorders (CIBERDEM), Madrid, Spain
| | - Núria Plana
- Spanish Biomedical Research Centre in Diabetes and Associated Metabolic Disorders (CIBERDEM), Madrid, Spain; Research Unit on Lipids and Atherosclerosis, Sant Joan University Hospital, Universitat Rovira i Virgili, IISPV, Reus, Spain
| | - Edmond Rock
- UMMM, INRA-Theix, St. Genes Champanelle, France
| | - Josep Ribalta
- Spanish Biomedical Research Centre in Diabetes and Associated Metabolic Disorders (CIBERDEM), Madrid, Spain; Research Unit on Lipids and Atherosclerosis, Sant Joan University Hospital, Universitat Rovira i Virgili, IISPV, Reus, Spain
| | - Oscar Yanes
- Department of Electronic Engineering, Universitat Rovira i Virgili, IISPV, Tarragona, Spain; Spanish Biomedical Research Centre in Diabetes and Associated Metabolic Disorders (CIBERDEM), Madrid, Spain
| | - Lluís Masana
- Spanish Biomedical Research Centre in Diabetes and Associated Metabolic Disorders (CIBERDEM), Madrid, Spain; Biosfer Teslab, Reus, Spain; Research Unit on Lipids and Atherosclerosis, Sant Joan University Hospital, Universitat Rovira i Virgili, IISPV, Reus, Spain
| | - Xavier Correig
- Department of Electronic Engineering, Universitat Rovira i Virgili, IISPV, Tarragona, Spain; Spanish Biomedical Research Centre in Diabetes and Associated Metabolic Disorders (CIBERDEM), Madrid, Spain; Biosfer Teslab, Reus, Spain
| |
Collapse
|
75
|
Matyus SP, Braun PJ, Wolak-Dinsmore J, Saenger AK, Jeyarajah EJ, Shalaurova I, Warner SM, Fischer TJ, Connelly MA. HDL particle number measured on the Vantera®, the first clinical NMR analyzer. Clin Biochem 2014; 48:148-55. [PMID: 25438074 DOI: 10.1016/j.clinbiochem.2014.11.017] [Citation(s) in RCA: 48] [Impact Index Per Article: 4.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/02/2014] [Revised: 11/10/2014] [Accepted: 11/17/2014] [Indexed: 01/18/2023]
Abstract
OBJECTIVES Nuclear magnetic resonance (NMR) spectroscopy has been successfully applied to the measurement of high-density lipoprotein (HDL) particles, providing particle concentrations for total HDL particle number (HDL-P), HDL subclasses (small, medium, large) and weighted, average HDL size for many years. Key clinical studies have demonstrated that NMR-measured HDL-P was more strongly associated with measures of coronary artery disease and a better predictor of incident cardiovascular disease (CVD) events than HDL-cholesterol (HDL-C). Recently, an NMR-based clinical analyzer, the Vantera(®), was developed to allow lipoprotein measurements to be performed in the routine, clinical laboratory setting. The aim of this study was to evaluate and report the performance characteristics for HDL-P quantified on the Vantera(®) Clinical Analyzer. DESIGN AND METHODS Assay performance was evaluated according to Clinical and Laboratory Standards Institute (CLSI) guidelines. In order to ensure that quantification of HDL-P on the Vantera(®) Clinical Analyzer was similar to the well-characterized HDL-P assay on the NMR profiler, a method comparison was performed. RESULTS The within-run and within-lab imprecision ranged from 2.0% to 3.9%. Linearity was established within the range of 10.0 to 65.0 μmol/L. The reference intervals were different between men (22.0 to 46.0 μmol/L) and women (26.7 to 52.9 μmol/L). HDL-P concentrations between two NMR platforms, Vantera(®) Clinical Analyzer and NMR Profiler, demonstrated excellent correlation (R(2) = 0.98). CONCLUSIONS The performance characteristics, as well as the primary tube sampling procedure for specimen analysis on the Vantera(®) Clinical Analyzer, suggest that the HDL-P assay is suitable for routine clinical applications.
Collapse
Affiliation(s)
| | | | | | - Amy K Saenger
- Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN, USA
| | | | | | | | | | | |
Collapse
|
76
|
Davidson WS. HDL-C vs HDL-P: how changing one letter could make a difference in understanding the role of high-density lipoprotein in disease. Clin Chem 2014; 60:e1-3. [PMID: 25281702 DOI: 10.1373/clinchem.2014.232769] [Citation(s) in RCA: 22] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/06/2022]
Affiliation(s)
- W Sean Davidson
- Center for Lipid and Arteriosclerosis Science, University of Cincinnati, Cincinnati OH.
| |
Collapse
|